Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nuvectis PharmaNVCT -1.61%22 EV-to-OCF is -30.97 as of Aug. 14, 2026. GuruFocus rates NVCT with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 1,410 Biotechnology companies, Nuvectis Pharma ranks better than 87.23% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Nuvectis Pharma's Enterprise Value is $604.22 Mil.
Nuvectis Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-19.51 Mil. Therefore, Nuvectis Pharma's EV-to-OCF for today is -30.97.
The historical rank and industry rank for Nuvectis Pharma's EV-to-OCF or its related term are showing as below:
NVCT'
s EV-to-OCF Range Over the Past 10 Years
Min: -30.97 Med: 0 Max: -30.97
Current: -30.97
During the past 6 years, the highest EV-to-OCF of Nuvectis Pharma was -30.97. The lowest was -30.97. And the median was .
NVCT's EV-to-OCF is ranked better than 87.23% of 1410
companies
in the Biotechnology industry
Industry Median: -3.52
vs NVCT: -30.97
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nuvectis Pharma's PE Ratio (TTM) for today is calculated as:
Nuvectis Pharma's share price for today is $19.225.
Nuvectis Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Nuvectis Pharma EV-to-OCF Related Terms
Nuvectis Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Nuvectis Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nuvectis Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvectis Pharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvectis Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Nuvectis Pharma's EV-to-OCF falls into.
Nuvectis Pharma's current Enterprise Value is $604.22 Mil.
Nuvectis Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvectis Pharma (NVCT) has a EV-to-OCF of -30.97 as of Aug. 14, 2026. According to the industry distribution chart, Nuvectis Pharma ranks #180 out of 1410 companies in the Biotechnology industry, placing it in the top 12.8%.
Is Nuvectis Pharma's EV-to-OCF too high?
Nuvectis Pharma's current EV-to-OCF is -30.97. Based on the distribution chart, Nuvectis Pharma ranks #180 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nuvectis Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Nuvectis Pharma's EV-to-OCF compare to IMMX and CBIO?
According to the Biotechnology industry distribution chart, Nuvectis Pharma ranks #180 out of 1410 companies for EV-to-OCF. This places Nuvectis Pharma in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Nuvectis Pharma's current EV-to-OCF is -30.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvectis Pharma stock overvalued right now?
Nuvectis Pharma (NVCT) has a current EV-to-OCF of -30.97. The current EV-to-OCF is -30.97. Nuvectis Pharma's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Nuvectis Pharma (NVCT), the current EV-to-OCF is -30.97 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
22GF Score
Get the complete analysis for NVCT
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVCT has been successfully added to your 
